Home Valeant raises offer for Dendreon assets to US$400 million to remain lead bidder
 

Keywords :   


Valeant raises offer for Dendreon assets to US$400 million to remain lead bidder

2015-02-05 18:29:47| Biotech - Topix.net

Valeant Pharmaceuticals International has raised its offer for the Provenge prostate cancer vaccine and other assets of U.S. drugmaker Dendreon Corp. by $100 million to $400 million. The Quebec-based company is the lead bidder in an auction supervised by a U.S. bankruptcy court.

Tags: offer lead million remain

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
17.05Register For Sustainable Cosmetics Summit
17.05Fewer crackers in Ritz boxes but price remains same
More »